MedTrace Logo

PHase IV Clinical Trial of Ceftriaxone Sodium and Sulbactam Sodium for Injection (CRO-SBT)

NCT04066621 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2019-08-28

No results posted yet for this study

Summary

To evaluate the safety and efficacy of treatment of children with acute bacterial infection disease with Ceftriaxone Sodium and Sulbactam Sodium for Injection in the condition of widely used, and provide the basis of adjusting the dosage regimen for children in particular.

Conditions

  • Respiratory Tract Infections
  • Urinary Tract Infections in Children

Interventions

DRUG

Ceftriaxone Sodium and Sulbactam Sodium for Injection

daily dose was 75 mg/kg by weight, 1-2 times ivgtt per day, 4 to 14 days

Sponsors & Collaborators

  • Xiangbei Welman Pharmaceutical Co., Ltd

    lead INDUSTRY

Principal Investigators

  • yuhua hu, Doctor · The First Affiliated Hospital with Nanjing Medical University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
6 Years
Max Age
14 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-04-28
Primary Completion
2016-06-11
Completion
2017-05-27

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04066621 on ClinicalTrials.gov